CRDF (Cardiff Oncology) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRDF Cardiff Oncology Inc CRDF
44 GF Score
Price $0.88
GF Value $1.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

CRDF
44GF Score
Cardiff Oncology Inc CRDF
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $0.88 is trading 37.1% below its estimated GF Value™ of $1.40. GuruFocus considers Cardiff Oncology to be Possible Value Trap.

Key valuation signals for CRDF:

  • Interest Received:
  • GF Value™: $1.40 vs. price of $0.88 (37.1% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
44GF Score

Get the complete analysis for CRDF

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.88
Price
$1.40
GF Value